These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28834373)

  • 41. Preschool ADHD Diagnosis and Stimulant Use Before and After the 2011 AAP Practice Guideline.
    Fiks AG; Ross ME; Mayne SL; Song L; Liu W; Steffes J; McCarn B; Grundmeier RW; Localio AR; Wasserman R
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Childhood stimulant treatment and teen depression: is there a relationship?
    Staikova E; Marks DJ; Miller CJ; Newcorn JH; Halperin JM
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):387-93. PubMed ID: 20973709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Body Mass Indices of Girls with and without ADHD: Developmental Trajectories from Childhood to Adulthood.
    Porter PA; Henry LN; Halkett A; Hinshaw SP
    J Clin Child Adolesc Psychol; 2022; 51(5):688-700. PubMed ID: 33625277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates.
    Brownell MD; Yogendran MS
    Can J Psychiatry; 2001 Apr; 46(3):264-72. PubMed ID: 11320681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The stability of children's weight status over time, and the role of television, physical activity, and diet.
    Jackson SL; Cunningham SA
    Prev Med; 2017 Jul; 100():229-234. PubMed ID: 28450122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
    Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD.
    Thiruchelvam D; Charach A; Schachar RJ
    J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):922-8. PubMed ID: 11501692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stimulant Treatment Trajectories Are Associated With Neural Reward Processing in Attention-Deficit/Hyperactivity Disorder.
    Schweren LJS; Groenman A; von Rhein D; Weeda W; Faraone SF; Luman M; van Ewijk H; Heslenfeld DJ; Franke B; Buitelaar JK; Oosterlaan J; Hoekstra PJ; Hartman CA
    J Clin Psychiatry; 2017 Jul; 78(7):e790-e796. PubMed ID: 28640989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stimulant and psychosocial treatment of ADHD in Latino/Hispanic children.
    Bauermeister JJ; Canino G; Bravo M; Ramírez R; Jensen PS; Chavez L; Martínez-Taboas A; Ribera J; Alegría M; García P
    J Am Acad Child Adolesc Psychiatry; 2003 Jul; 42(7):851-5. PubMed ID: 12819445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
    Fredriksen M; Halmøy A; Faraone SV; Haavik J
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics.
    Bussing R; Narwaney KJ; Winterstein AG; Newton DA; DeBar L; Boscarino JA; Toh S; Pawloski P; Nordin JD; Herrinton LJ; Mason D; Daley MF
    Curr Med Res Opin; 2014 Aug; 30(8):1687-99. PubMed ID: 24635013
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Household Diversion of Prescription Stimulants: Medication Misuse by Parents of Children with Attention-Deficit/Hyperactivity Disorder.
    Pham T; Milanaik R; Kaplan A; Papaioannou H; Adesman A
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):741-746. PubMed ID: 28686059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving psychostimulant adherence in children with ADHD.
    Charach A; Gajaria A
    Expert Rev Neurother; 2008 Oct; 8(10):1563-71. PubMed ID: 18928348
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants.
    Schweren LJ; Hartman CA; Heslenfeld DJ; van der Meer D; Franke B; Oosterlaan J; Buitelaar JK; Faraone SV; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2015 Aug; 54(8):660-7. PubMed ID: 26210335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
    Díez-Suárez A; Vallejo-Valdivielso M; Marín-Méndez JJ; de Castro-Manglano P; Soutullo CA
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):723-730. PubMed ID: 28817309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.
    Poulton A
    Expert Rev Neurother; 2006 Apr; 6(4):551-61. PubMed ID: 16623654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
    Van Brunt DL; Johnston JA; Ye W; Pohl GM; Sun PJ; Sterling KL; Davis ME
    Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.